Ranbaxy receives USFDA approval for esomeprazole capsules
Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration for esomeprazole magnesium delayed-release capsules, 20 mg (base) and 40 mg (base).
By INDIATIMES NEWS NETWORK |
MUMBAI: Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration for esomeprazole magnesium delayed-release capsules, 20 mg (base) and 40 mg (base). Nexium (Esomeprazole) is the second largest selling drug in US with total annual market sales of $5.5 billion.
Ranbaxy believes that it has a first to file status on the drug, providing it with a potential 180-day marketing exclusivity.
Esomeprazole is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis, to maintain symptom resolution and healing of erosive esophagitis and for treatment of heartburn and other symptoms associated with Gastroesophageal Reflux Disease.
At 12:14 pm, Ranbaxy Laboratories shares were up 0.05 per cent at Rs 382.25 on NSE.
Ranbaxy believes that it has a first to file status on the drug, providing it with a potential 180-day marketing exclusivity.
Esomeprazole is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis, to maintain symptom resolution and healing of erosive esophagitis and for treatment of heartburn and other symptoms associated with Gastroesophageal Reflux Disease.
At 12:14 pm, Ranbaxy Laboratories shares were up 0.05 per cent at Rs 382.25 on NSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
